Top-News
Biotechnologie Niederlande

Lava Therapeutics NV Aktie

Aktie
WKN:  A2QSJY ISIN:  NL0015000AG6 US-Symbol:  LVTX
1,26 $
+0,02 $
+1,61%
1,1143 € 20:28:20 Uhr
Depot/Watchlist
Aktienanzahl *
26,30 Mio.
Marktkapitalisierung *
29,02 Mio. €
Streubesitz
21,20%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.02.2025

Lava Therapeutics NV News

06.03.24 - PR Newswire
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird? PR Newswire
01.03.24 - PR Newswire
Thinking about buying stock in Societal CDMO, LAVA Therapeutics, Eastman Kodak, Brightspring Health Services, or Codexis?
Thinking about buying stock in Societal CDMO, LAVA Therapeutics, Eastman Kodak, Brightspring Health Services, or Codexis? PR Newswire
25.01.24 - PR Newswire
Thinking about buying stock in LAVA Therapeutics, UP Fintech Holding, Babcock & Wilcox Enterprises, Safety Shot, or eFFECTOR Therapeutics?
Thinking about buying stock in LAVA Therapeutics, UP Fintech Holding, Babcock & Wilcox Enterprises, Safety Shot, or eFFECTOR Therapeutics? PR Newswire
26.09.22 - PR Newswire
Thinking about buying stock in LAVA Therapeutics, Faraday Future Intelligent Electric, Melco Resorts & Entertainment, American Virtual Cloud Technologies, or Trip.com?
Thinking about buying stock in LAVA Therapeutics, Faraday Future Intelligent Electric, Melco Resorts & Entertainment, American Virtual Cloud Technologies, or Trip.com? PR Newswire
07.10.21 - GlobeNewswire
CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. ...
16.08.21 - GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies
27.07.21 - GlobeNewswire
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-​stage biotechnology company focused ...
13.07.21 - GlobeNewswire
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-​in-class gamma-​delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia
25.05.21 - GlobeNewswire
LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its ...
20.05.21 - GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023
18.05.21 - GlobeNewswire
LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its ...
01.04.21 - GlobeNewswire
LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its ...

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »